These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6203549)

  • 1. The influence of L-asparaginase therapy on the fibrinolytic system.
    Vellenga E; Kluft C; Mulder NH; Wijngaards G; Nieweg HO
    Br J Haematol; 1984 Jun; 57(2):247-54. PubMed ID: 6203549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified crossed immunoelectrophoresis to study with whole plasma the reversible complex formation of histidine-rich glycoprotein with plasminogen.
    Kluft C; Los P
    Thromb Haemost; 1988 Dec; 60(3):411-4. PubMed ID: 2467400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.
    Kluft C; Vellenga E; Brommer EJ; Wijngaards G
    Blood; 1982 Jun; 59(6):1169-80. PubMed ID: 6177359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
    Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
    Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy.
    Nowak-Göttl U; Rath B; Binder M; Hassel JU; Wolff J; Husemann S; Ritter J
    Haematologica; 1995; 80(5):451-3. PubMed ID: 8566890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
    McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
    Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia.
    Semeraro N; Montemurro P; Giordano P; Schettini F; Santoro N; De Mattia D; Giordano D; Conese M; Colucci M
    Thromb Haemost; 1990 Aug; 64(1):38-40. PubMed ID: 2274927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes of fibrinolysis during labour with and without aprotinin application].
    Kühnert M; Stein W; Tekesin I; Hellmeyer L; Schmidt S
    Z Geburtshilfe Neonatol; 2003; 207(3):90-100. PubMed ID: 12891467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
    Korninger C; Collen D
    Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
    Carpenter SL; Mathew P
    Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and secretion of the fibrinolytic components, including alpha 2-antiplasmin, by a human hepatoma cell line.
    Fair DS; Plow EF
    J Lab Clin Med; 1983 Mar; 101(3):372-84. PubMed ID: 6186756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
    Nowak-Göttl U; Werber G; Ziemann D; Ahlke E; Boos J
    Haematologica; 1996; 81(2):127-31. PubMed ID: 8641640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.